https://www.selleckchem.com/products/GDC-0449.html
Teprotumumab, an IGF-1 receptor antibody, was effective in treating GO patients in a phase III trial and should soon be awarded approval for Europe. The current therapy concept for Graves' orbitopathy is as follows first anti-inflammatory therapy then surgical correction of the permanent defects. This may soon be modified, due to the use of targeted therapies. The current therapy concept for Graves' orbitopathy is as follows first anti-inflammatory therapy then surgical correction of the permanent defects. This may soon be modified, du
Like
Comment
Share
